Immunome, Inc. (IMNM)
18.71
+0.80
(+4.50%)
USD |
NASDAQ |
Nov 06, 16:00
19.49
+0.78
(+4.17%)
After-Hours: 20:00
Immunome Cash from Operations (Quarterly) : -61.69M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -61.69M |
| March 31, 2026 | -58.64M |
| December 31, 2025 | -47.95M |
| September 30, 2025 | -40.51M |
| June 30, 2025 | -49.40M |
| March 31, 2025 | -53.06M |
| December 31, 2024 | -42.06M |
| September 30, 2024 | -34.17M |
| June 30, 2024 | -23.40M |
| March 31, 2024 | -11.17M |
| December 31, 2023 | -17.46M |
| September 30, 2023 | -8.614M |
| June 30, 2023 | -5.668M |
| Date | Value |
|---|---|
| March 31, 2023 | 24.17M |
| December 31, 2022 | -6.683M |
| September 30, 2022 | -7.571M |
| June 30, 2022 | -8.06M |
| March 31, 2022 | -6.376M |
| December 31, 2021 | -6.805M |
| September 30, 2021 | -4.145M |
| June 30, 2021 | -3.741M |
| March 31, 2021 | -3.535M |
| December 31, 2020 | -6.062M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | -2.064M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Revolution Medicines, Inc. | -415.65M |
| Erasca, Inc. | -27.27M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -304.35M |
| Cash from Financing (Quarterly) | 1.058M |
| Free Cash Flow | -219.09M |
| Free Cash Flow Per Share (Quarterly) | -0.5638 |
| Free Cash Flow to Equity (Quarterly) | -64.91M |
| Free Cash Flow to Firm (Quarterly) | -63.87M |
| Free Cash Flow Yield | -11.50% |